ADAP - Adaptimmune Therapeutics Plc Stock Price, Fair Value and News

$0.65-0.01 (-1.52%)

Delayed as of 21 Nov 2024, 09:59 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ADAP Price Action

Last 7 days

-14.3%

Last 30 days

-19.5%

Last 90 days

-43.6%

Trailing 12 Months

50%

ADAP RSI Chart

ADAP Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

-22.76

Price/Sales (Trailing)

19.61

EV/EBITDA

-29.31

Price/Free Cashflow

-18.37

ADAP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ADAP Fundamentals

ADAP Revenue

Revenue (TTM)

60.3M

Rev. Growth (Yr)

458.83%

Rev. Growth (Qtr)

-68.1%

ADAP Earnings

Earnings (TTM)

-44.5M

Earnings Growth (Yr)

61.37%

Earnings Growth (Qtr)

-125.34%

ADAP Profitability

EBT Margin

-71.81%

Return on Equity

-55.65%

Return on Assets

-14.02%

Free Cashflow Yield

-5.44%

ADAP Investor Care

Shares Dilution (1Y)

12.66%

Diluted EPS (TTM)

-0.04

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	71.2M	70.8M	71.1M	60.3M
2022	9.3M	11.7M	17.5M	27.1M
2021	3.6M	6.2M	6.2M	6.1M
2020	1.7M	2.2M	3.2M	4.0M
2019	0	40.0M	20.6M	1.1M
2018	43.2M	48.7M	62.3M	59.5M
2017	14.1M	17.3M	42.1M	37.8M
2016	14.7M	12.2M	9.7M	14.2M
2015	5.3M	9.9M	12.2M	14.5M
2014	0	825.0K	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

CEO	Mr. Adrian G. Rawcliffe
WEBSITE	adaptimmune.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	534

Adaptimmune Therapeutics Plc Frequently Asked Questions

What is the ticker symbol for Adaptimmune Therapeutics Plc? What does ADAP stand for in stocks?

ADAP is the stock ticker symbol of Adaptimmune Therapeutics Plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adaptimmune Therapeutics Plc (ADAP)?

As of Wed Nov 20 2024, market cap of Adaptimmune Therapeutics Plc is 1.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADAP stock?

You can check ADAP's fair value in chart for subscribers.

Is Adaptimmune Therapeutics Plc a good stock to buy?

The fair value guage provides a quick view whether ADAP is over valued or under valued. Whether Adaptimmune Therapeutics Plc is cheap or expensive depends on the assumptions which impact Adaptimmune Therapeutics Plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADAP.

What is Adaptimmune Therapeutics Plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, ADAP's PE ratio (Price to Earnings) is -22.76 and Price to Sales (PS) ratio is 19.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADAP PE ratio will change depending on the future growth rate expectations of investors.